KKR Income Opportunities Fund
Change company Symbol lookup
Select an option...
KIO KKR Income Opportunities Fund
BOAS BOA Acquisition Corp
ESBA Empire State Realty OP LP
ASGN ASGN Inc
CMS CMS Energy Corp
POWRU Powered Brands
VLDRW Velodyne Lidar Equity Warrants Exp 29 Sep 2025 *W EXP 09/29/2025
JPM JPMorgan Chase & Co
UVV Universal Corp
LNC Lincoln National Corp
Go

Company profile

KKR Income Opportunities Fund (Fund) is a closed-end registered management investment company. The Fund’s primary investment objective is to seek a high level of current income with a secondary objective of capital appreciation. The fund is primarily engaged in investing targeted portfolio of loans and fixed-income instruments (including derivatives) of United States and non-United States issuers and implementing hedging strategies in order to seek to achieve attractive risk-adjusted returns. The Fund invests at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments. The Fund's investment advisor is KKR Credit Advisors (US) LLC.

Closing Price
$15.71
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
70,178
0

Medexus Pharmaceuticals Announces Appointment of Internal Counsel

8:30 am ET November 8, 2021 (Globe Newswire) Print

Medexus Pharmaceuticals Inc. ("Medexus" or the "Company") (TSX: MDP) (OTCQX: MEDXF) today announced that it has appointed Ian C Wildgoose Brown as the Company's general counsel and corporate secretary. In this role, Mr. Wildgoose Brown will work with the rest of the Medexus management team to further strengthen and expand the Company's commercial platform and product portfolio.

Mr. Wildgoose Brown is a corporate lawyer who brings to this role a decade of experience with complex business transactions and general corporate governance. Before joining Medexus, Mr. Wildgoose Brown held senior positions with WeWork and its associated real estate investment platform, where his responsibilities included strategic transactional and corporate-development projects. He was previously an associate lawyer with Debevoise & Plimpton and WilmerHale, where he focused on corporate and securities transactions for companies in the life-sciences and financial sectors. Mr. Wildgoose Brown holds a Juris Doctor from Harvard Law School, a Master of Science in Law & Finance from the University of Oxford, a Bachelor of Arts from Queen's University at Kingston, and is admitted to practice law in New York.

Ken d'Entremont, CEO of Medexus, stated, "We are glad to have Mr. Wildgoose Brown join our team as general counsel. As we continue to evaluate new opportunities to grow our portfolio, strengthening our team remains a priority. Ian's significant experience in mergers and acquisitions, join ventures, and other corporate finance initiatives will undoubtedly be an asset as we grow our business organically and engage in other business development initiatives."

About Medexus

Medexus is a leader in innovative rare disease treatment solutions with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company's vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of hematology, auto-immune disease, and allergy. The Company's leading products are: Rasuvo(TM) and Metoject, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B - a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall, an innovative prescription allergy medication with a unique mode of action. The Company has also licensed treosulfan, a preparative regimen for allogeneic hematopoietic stem cell transplantation to be used in combination with fludarabine, from medac GmbH for Canada and the United States.

For more information, please contact:

Ken d'Entremont, Chief Executive Officer

Medexus Pharmaceuticals Inc.

Tel.: 905-676-0003

E-mail: ken.dentremont@medexus.com

Marcel Konrad, Chief Financial Officer

Medexus Pharmaceuticals Inc.

Tel.: 312-548-3139

E-mail: marcel.konrad@medexus.com

Investor Relations (U.S.):

Crescendo Communications, LLC

Tel: +1-212-671-1020

Email: mdp@crescendo-ir.com

Investor Relations (Canada):

Tina Byers

Adelaide Capital

Tel: 905-330-3275

E-mail: tina@adcap.ca

https://ml.globenewswire.com/media/fb381377-78d1-4571-a5bc-1ab43286a6ac/small/medexus-pharma-mpi-pms-logo-jpg.jpg

https://ml.globenewswire.com/media/fb381377-78d1-4571-a5bc-1ab43286a6ac/small/medexus-pharma-mpi-pms-logo-jpg.jpg

comtex tracking

COMTEX_396512274/2010/2021-11-08T08:30:04

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.